Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for ADHD in Marijuana-Abusing Teens
NCT00142961Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Oct 2005
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by New York State Psychiatric Institute. Primary endpoint: ADHD response and reduction in ADHD symptoms at 12 weeks. Started Oct 2005; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00142961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00142961.